Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba®
2012-10-18 · Novo Nordisk A/S · original novonordisk.com ↗
Novo Nordisk today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has published their assessment report of Tresiba® (insulin degludec). The report forms the basis of the approval of the product announced on 28 September 2012. Further information: Media: Investors: Mike Rulis Kasper Roseeuw Poulsen Tel: (+45) 3079 3573 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ambre Morley Jannick Lindegaard Tel: (+1) 609 216 5240 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 65 / 2012
The release as fetched from its publisher. novonordisk.com ↗